Luo X; Yu Ji-Xian, Xie L, Ma Wen-Jun, Wang Li-Hong

Idioma: Ingles.
Referencias bibliográficas: 20
Paginas: 888-892
Archivo PDF: 132.78 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39(3): 857-61.

2. Lai CL, Ratziu V, Yuen MF, Thierry P. Viral hepatitis B. Lancet 2003; 362(9401): 2089-94

3. Chen Y, Chen YP, Tao RF. The research progress of chronic hepatitis B. China Medicine 2011; 6(4): 500-2.

4. Ren X, Xu Z, Liu Y, Li X, Bai S, Ding N, Zhong Y, et al. Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. J Viral Hepatology 2010; 17(12): 887-95.

5. Jiang ZW and Liu X. The study of the consequence about α- interferon and Hepatitis B virus genotype of B and C on the treatment of chronic Hepatitis B. Modern Medicine 2013; 41(3): 205-7.

6. Zhang WW, Han ZY. The study of the consequence about acupoint injection α-interferon on the treatment of chronic Hepatitis B. China’s health care nutrition 2012; 2(7): 1767-8.

7. Li WL, Wu MS, Huang YB. The expression of peripheral blood mononuclear cells TLR4 and the change of serum type Th1/Th2 cytokines on the α-interferon treatment of chronic Hepatitis B. Practical Hepatology 2012; 15(4): 315-17.

8. Chinese Society of Hepatology and Chinese Society of Infectious Diseases: The guideline of prevention and treatment of chronic hepatitis B (2010). Chin J Hepatol 2011; 19(1): 13-24.

9. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001; 120: 1828-53.

10. Li HQ, Li H. The antiviral mechanism and effect of interferon on viral hepatitis. China Public Health 2005; 22(7): 890-91.

11. Xu BF, Fan QL, Wei W, Song LH. The advance of the antihepatitis virus mechanisms about α-interferon and peg-interferon. Chinese Pharmacological Bulletin 2008; 14(10): 1276-9.

12. Lin Q, Yu XP, Su ZJ. The curative effect analysis of partial response of nucleoside analogues on the treatment of chronic hepatitis B to continue with the alpha interferon. Practical Hepatology 2013; 16(3): 232-4.

13. You CY. Analysis of the adverse drug reactions of α-interferon on the treatment of chronic hepatitis B. Clinical rational Drug Use 2013; 6(2): 53.

14. Li Z. The clinical observation of Peg-interferon α-2 a180 μg combined with adefovir on the treatment of chronic hepatitis B. The latest medical information abstract 2012; 12(10): 267-268.

15. Shi YY. The clinical observation of peg-interferon compared with conventional interferon on treatment of 60 cases of chronic hepatitis B. Public Medical Forum 2015; 19(5): 640-2.

16. Wang Y, Liu SM. The research of the side effects and clinical significance of alpha interferon on the treatment of chronic hepatitis B. Chin J Biochem Pharm 2014, 7(34): 126-8.

17. Chen YF, Zhang W, Qiu LL. The effect comparison of Peg-interferon with conventional interferon on treatment of chronic hepatitis B. Clinical Medical 2013; 22(7): 94-5.

18. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, Chutaputti A, et al. Peginterferon α-2a(40 kDa): an advance in the treatment of hepatitis B e antigenpositive chronic hepatitis B. J Viral Hepatitis 2003; 10: 298-305.

19. Chan HL, Wong VW, Chim AM, Lai HC, Huang CF, Hsieh MY, Huang JF, et al. Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha-2a. Antiviral therapy 2008; 13: 555-62.

20. Tangkijvanich P, Komolmit P, Mahachai V, Sa-Nguanmoo P, Theamboonlers A, Poovorawan Y. Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon α-2b therapy in hepatitis B eantigen- positive chronic hepatitis B. Hepatology Research 2010; 40: 269-77.